AZD8055

Name: AZD8055
Brand: Selleck Chemicals
SKU: S1555
Rating: 5 (138 reviews)

For research use only.

Catalog No.S1555

138 publications

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Selleck's AZD8055 has been cited by 138 publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):107

PubMed: 32517736 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):882-894

PubMed: 31879363 ( click the link to review the publication )

J Cancer, 2020, 15;11(12):3492-3501

PubMed: 32284745 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):4025

PubMed: 32132574 ( click the link to review the publication )

J Biol Chem, 2020, 22;295(21):7418-7430

PubMed: 32312748 ( click the link to review the publication )

Biosci Rep, 2020, 30;40(4):BSR20200905

PubMed: 32285908 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 23;S0006-291X(20)30951-7

PubMed: 32456793 ( click the link to review the publication )
G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106241

PubMed: 32058927 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )
Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4561-4566

PubMed: 30214591 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):632-642

PubMed: 29928450 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(15):2074-2084

PubMed: 27748760 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Anticancer Res, 2017, 37(3):1083-1090

PubMed: 28314268 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )
EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: 25725958 ( click the link to review the publication )
J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Clin Sci (Lond), 2015, 128(8):517-26

PubMed: 25428582 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )
Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

EMBO J, 2013, 28;32(17):2377-91

PubMed: 23921550 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwMEKzN\|Eh\|ryP	NGryUWVUSU6JRWK=
NCI-H720	NVzUeGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwMEK5N\|gh\|ryP	M4fBNXNCVkeHUh?=
KARPAS-45	M1\lbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;nUVZKSzVyPUCuNFM{PzFizszN	NWPP[JdzW0GQR1XS
EW-3	NV;vOZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwMESwOVYh\|ryP	MXHTRW5ITVJ?
SBC-1	NXLFPFJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;lcpBKSzVyPUCuNFQ2QDFizszN	MX3TRW5ITVJ?
NCI-H209	NXnrRWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\yPFZNUUN3ME2wMlA2PDV\|IN88US=>	NWjHUHA2W0GQR1XS
EoL-1-cell	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTBwME[1Olkh\|ryP	M{nTU3NCVkeHUh?=
H9	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\wRWFJUUN3ME2wMlA3Pjl{IN88US=>	NUKzeWlxW0GQR1XS
AN3-CA	NUfFXYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXEUlJJUUN3ME2wMlA4QTVzIN88US=>	MlviV2FPT0WU
HH	NWT4ZYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vBPGlEPTB;MD6wPFAxQSEQvF2=	NIfJZYtUSU6JRWK=
KU812	M2LBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvsUlZyUUN3ME2wMlA5ODR\|IN88US=>	M13mU3NCVkeHUh?=
DU-4475	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzOW3NKSzVyPUCuNFgxPDdizszN	MknNV2FPT0WU
CTV-1	NFPxZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3VTWM2OD1yLkC4OlQyKM7:TR?=	M3\2SHNCVkeHUh?=
BV-173	NGDFNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHFV2pKSzVyPUCuNFkxPjFizszN	MWjTRW5ITVJ?
ES5	M17EbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETT[mVKSzVyPUCuNFk{PSEQvF2=	NXf5[\|E6W0GQR1XS
G-402	NInCVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHT3TWRKSzVyPUCuNFk6QCEQvF2=	NWfGN2xVW0GQR1XS
MV-4-11	NHrCXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSyTWM2OD1yLkGwN\|Q4KM7:TR?=	NH7yVXJUSU6JRWK=
NB69	NWXUSZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3vbYp7UUN3ME2wMlE{PSEQvF2=	NH\ycmpUSU6JRWK=
EGI-1	M3rJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIS2[mRKSzVyPUCuNVM2OzFizszN	MVXTRW5ITVJ?
EW-18	NUW3WI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4noO2lEPTB;MD6xOFA4OyEQvF2=	NWm3PHZNW0GQR1XS
ME-180	NHL5flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LVS2lEPTB;MD6xOFY5OSEQvF2=	NYSxUm83W0GQR1XS
D-283MED	NGDhRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTBwMUS3NlMh\|ryP	NXn5Z4V5W0GQR1XS
NB14	M2jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnLdJNKSzVyPUCuNVY1PDdizszN	NVyyZWxiW0GQR1XS
Ramos-2G6-4C10	M{XBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTBwMU[5PFMh\|ryP	MVPTRW5ITVJ?
NBsusSR	NGm4O3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TFTmlEPTB;MD6xO\|AyQSEQvF2=	NVrOV\|FXW0GQR1XS
LAMA-84	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7R[Ws1UUN3ME2wMlE5ODN{IN88US=>	NF62R29USU6JRWK=
NCI-H1581	NYO0SGpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonsTWM2OD1yLkG4PVY3KM7:TR?=	NYf4fnRWW0GQR1XS
A204	NIrySWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT6d2NKSzVyPUCuNVg6PyEQvF2=	NVzYd21RW0GQR1XS
A549	NHy4eoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTBwMUm1OUDPxE1?	Ml\DV2FPT0WU
CAL-51	NIDNfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\tTWM2OD1yLkG5OlUyKM7:TR?=	MUPTRW5ITVJ?
NKM-1	NHLE[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwMkCwNlkh\|ryP	MoLwV2FPT0WU
LoVo	NX7hbJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;pTWM2OD1yLkKwNlAzKM7:TR?=	NEHaRllUSU6JRWK=
HAL-01	M2LOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rIS2lEPTB;MD6yNFI6PyEQvF2=	M{\HZ3NCVkeHUh?=
HCC2218	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jGS2lEPTB;MD6yNFY5QCEQvF2=	Mom5V2FPT0WU
BEN	NUfiV5JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInC[4RKSzVyPUCuNlEzQTNizszN	NWjEeHlUW0GQR1XS
LC-2-ad	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPzTWM2OD1yLkKyNFg1KM7:TR?=	NXrFfZl2W0GQR1XS
LXF-289	NXH6R3RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjuTWM2OD1yLkK1NFQyKM7:TR?=	MVrTRW5ITVJ?
HGC-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMk[0NVQh\|ryP	NFWwdIVUSU6JRWK=
LK-2	NWfVU\|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXOR5J5UUN3ME2wMlI3QDJ2IN88US=>	MkHCV2FPT0WU
CTB-1	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TzbGlEPTB;MD6yO\|IyPSEQvF2=	MlToV2FPT0WU
697	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj5[ZpRUUN3ME2wMlI4OzZ5IN88US=>	MXvTRW5ITVJ?
ES7	M1HkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rZbmlEPTB;MD6yO\|M5OyEQvF2=	M4rXSnNCVkeHUh?=
MG-63	M3PHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfldZF4UUN3ME2wMlI4PDB5IN88US=>	NHPnWFVUSU6JRWK=
T47D	NVrXd3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jnXGlEPTB;MD6yO\|Q4PSEQvF2=	MnLhV2FPT0WU
RPMI-8226	NFjINpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrzOpNKSzVyPUCuNlg2QDlizszN	M3K5U3NCVkeHUh?=
NCI-H292	M{nYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGOyVZlKSzVyPUCuNlkyPjRizszN	MV7TRW5ITVJ?
HT	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4qwV2lEPTB;MD6yPVM5KM7:TR?=	NYnRb3BnW0GQR1XS
A3-KAW	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGToT2tKSzVyPUCuNlk4PCEQvF2=	MorSV2FPT0WU
LB2241-RCC	NH7OSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjPZlhKSzVyPUCuN\|AyQThizszN	NHr6SVdUSU6JRWK=
BB65-RCC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLtV4k{UUN3ME2wMlMxQDB3IN88US=>	M{\pVHNCVkeHUh?=
G-401	NEjmUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDa[mF3UUN3ME2wMlMxQTh4IN88US=>	M4\JenNCVkeHUh?=
TYK-nu	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTBwM{G4OlQh\|ryP	M1P1SnNCVkeHUh?=
NCI-SNU-1	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzKTWM2OD1yLkOyN\|MyKM7:TR?=	M1r0ZXNCVkeHUh?=
CHL-1	NV7RUopNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnZWVNVUUN3ME2wMlMzPzB\|IN88US=>	MlrmV2FPT0WU
P30-OHK	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L4[mlEPTB;MD6zNlcxPSEQvF2=	MXzTRW5ITVJ?
PA-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn[2TWM2OD1yLkOzOlE6KM7:TR?=	M1rMTXNCVkeHUh?=
LB1047-RCC	M17Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlWzTWM2OD1yLkO0NFQ4KM7:TR?=	MYTTRW5ITVJ?
EM-2	NYW5dmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDVUXRKSzVyPUCuN\|QyQDhizszN	M2q0ZXNCVkeHUh?=
VA-ES-BJ	NFX3PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXI[3Q4UUN3ME2wMlM1OjZ6IN88US=>	NFO3dllUSU6JRWK=
NCI-H520	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LLdGlEPTB;MD6zOFg{PCEQvF2=	NYe2XJV1W0GQR1XS
ECC10	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DsdWlEPTB;MD6zOVA{PSEQvF2=	M3K1U3NCVkeHUh?=
LNCaP-Clone-FGC	NVexdYlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rLOmlEPTB;MD6zOVMyPCEQvF2=	NV[0OYdmW0GQR1XS
ES8	NWfUSZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr4eZd1UUN3ME2wMlM3PTV\|IN88US=>	MmfrV2FPT0WU
HuO-3N1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrKTWM2OD1yLkO4N\|c6KM7:TR?=	MVfTRW5ITVJ?
L-363	NEHYXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjTU3pKUUN3ME2wMlM6ODJ4IN88US=>	MkjhV2FPT0WU
SK-LU-1	NE\CPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVOySZdKUUN3ME2wMlM6OjB6IN88US=>	NGTFOYVUSU6JRWK=
MCF7	NIHM[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTDTWM2OD1yLkSwOVMh\|ryP	NYm3dY1QW0GQR1XS
HuO9	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jvdWlEPTB;MD60NFY3PyEQvF2=	NWDmZlBbW0GQR1XS
BHT-101	NFmxR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXpcZlSUUN3ME2wMlQxPzh5IN88US=>	MmXlV2FPT0WU
MZ2-MEL	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\HXW5PUUN3ME2wMlQxQDh{IN88US=>	MWLTRW5ITVJ?
NOS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:zOpRKSzVyPUCuOFExPzRizszN	NGDVWopUSU6JRWK=
NEC8	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX73VJB3UUN3ME2wMlQyPjl3IN88US=>	M1rye3NCVkeHUh?=
COR-L88	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTBwNEKyOlch\|ryP	M1nJfHNCVkeHUh?=
MFM-223	NVm0NnBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwNEK2NVch\|ryP	NVqxXHFjW0GQR1XS
HSC-3	NH\HNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTBwNEK5NFgh\|ryP	NWnTbm9WW0GQR1XS
OVCAR-5	NHXSZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHOTWM2OD1yLkSyPVM{KM7:TR?=	NIX5coNUSU6JRWK=
MFE-280	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkW5TWM2OD1yLkSzNFMzKM7:TR?=	NYXLVY03W0GQR1XS
KP-N-YS	M3:5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfRTWM2OD1yLkSzNFch\|ryP	MYjTRW5ITVJ?
EPLC-272H	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7DTWM2OD1yLkSzNFc4KM7:TR?=	NVnsS3RtW0GQR1XS
KE-37	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfKRppKSzVyPUCuOFMzPDdizszN	MofYV2FPT0WU
HuH-7	MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTBwNEOzO\|Ih\|ryP	MW\TRW5ITVJ?
CHP-212	NG\tXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrOUGRKSzVyPUCuOFM3QTdizszN	NYj5d5FkW0GQR1XS
SK-MES-1	M4rISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDtTWM2OD1yLkSzPFQ5KM7:TR?=	NYLQXYk5W0GQR1XS
SJSA-1	NVXLfIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwNES1OVQh\|ryP	NXi5RYdDW0GQR1XS
QIMR-WIL	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XHVGlEPTB;MD60OVE2KM7:TR?=	MVvTRW5ITVJ?
ES4	M{LMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV24W2w6UUN3ME2wMlQ2OzN4IN88US=>	NGTpSJJUSU6JRWK=
TI-73	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH64PVlKSzVyPUCuOFU3QDZizszN	M2fVU3NCVkeHUh?=
COLO-684	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\xVZdKSzVyPUCuOFU4OjZizszN	NH7Wb5hUSU6JRWK=
GCIY	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTBwNEW3OVQh\|ryP	NVPPXIJ3W0GQR1XS
JVM-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{npSGlEPTB;MD60OlI6OiEQvF2=	MUnTRW5ITVJ?
MPP-89	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFWzfIFKSzVyPUCuOFY6PDdizszN	NXTOeY52W0GQR1XS
M14	M3PI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwNEexO{DPxE1?	NHS4bXNUSU6JRWK=
SW962	NEn6O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnBWolKSzVyPUCuOFcyQSEQvF2=	NH3ad4xUSU6JRWK=
VM-CUB-1	NUfrToFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\TU3BKSzVyPUCuOFczQDZizszN	MnzKV2FPT0WU
A101D	NULPfph3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVq3W4g6UUN3ME2wMlQ5QTZ6IN88US=>	MWXTRW5ITVJ?
DB	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4WydWlEPTB;MD61NFAzOSEQvF2=	Mn;2V2FPT0WU
KNS-62	NVjSbpRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PJS2lEPTB;MD61NFU3QCEQvF2=	NGnaTnRUSU6JRWK=
NCI-H460	NEfWcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwNUC1PVch\|ryP	MYDTRW5ITVJ?
MDA-MB-361	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTBwNUC4O{DPxE1?	MnLUV2FPT0WU
DOK	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\DTWM2OD1yLkWxN\|M{KM7:TR?=	MoXzV2FPT0WU
CAL-39	NHvOVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwNUKyOlgh\|ryP	MX3TRW5ITVJ?
HT-1080	NYTLRmlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fpZWlEPTB;MD61NlU1OyEQvF2=	MWrTRW5ITVJ?
GR-ST	M13OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XrdWlEPTB;MD61N\|AyPSEQvF2=	M1zSTHNCVkeHUh?=
J-RT3-T3-5	NGLIT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXWwV2p1UUN3ME2wMlU{OTl3IN88US=>	NXzaO2E3W0GQR1XS
NCI-H1793	M1PFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ntVmlEPTB;MD61N\|Q1PyEQvF2=	MonJV2FPT0WU
NCI-H1355	NFuyNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TYRWlEPTB;MD61N\|g4QCEQvF2=	M4jvTXNCVkeHUh?=
YH-13	NGHlRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3z6cmlEPTB;MD61OFk{QCEQvF2=	MWjTRW5ITVJ?
LOXIMVI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfC[3VUUUN3ME2wMlU2OTJ\|IN88US=>	MmXXV2FPT0WU
ES1	M{PsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnofnJKSzVyPUCuOVU2OThizszN	MmjDV2FPT0WU
GAMG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwNUW2OVgh\|ryP	MnjaV2FPT0WU
SK-MEL-28	M{Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwNUW5NUDPxE1?	NFvlPYdUSU6JRWK=
KG-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIK4PY9KSzVyPUCuOVY5QDRizszN	MoXTV2FPT0WU
HOS	M2C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnTdFNKSzVyPUCuOVcyQTJizszN	M{nZXHNCVkeHUh?=
PANC-08-13	NUjtbmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwNUezPFkh\|ryP	M3rUcXNCVkeHUh?=
SW780	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTBwNUe1PVUh\|ryP	NWHxSXBlW0GQR1XS
MDA-MB-175-VII	M3K3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPvZYZKSzVyPUCuOVc4PDFizszN	NH35UopUSU6JRWK=
MSTO-211H	NYXO[FVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHjTWM2OD1yLkW3O\|UyKM7:TR?=	MmjiV2FPT0WU
ML-2	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwNUi0O\|gh\|ryP	M3v6UXNCVkeHUh?=
SCC-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPP[ohKSzVyPUCuOVg2PDFizszN	MoXGV2FPT0WU
NCI-H1048	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\ZTXdKSzVyPUCuOVg3PDVizszN	NIfMc\|FUSU6JRWK=
NCI-H28	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4K2NGlEPTB;MD61PFY4PSEQvF2=	NFzPVVVUSU6JRWK=
BCPAP	NYXXfZd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\BTWM2OD1yLkW4O\|kyKM7:TR?=	MofsV2FPT0WU
PC-14	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwNUi5O{DPxE1?	M2LGZXNCVkeHUh?=
OAW-42	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwNUmxOlIh\|ryP	MkXSV2FPT0WU
IA-LM	NIHMcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwNUm2NFkh\|ryP	M4jt[3NCVkeHUh?=
Hs-578-T	M{X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXCTWM2OD1yLkW5PFUyKM7:TR?=	NE[0RW9USU6JRWK=
H4	NFLQbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\HcWlEPTB;MD62NFA6PCEQvF2=	M3\wd3NCVkeHUh?=
HL-60	NULUcmpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTBwNkCzOVEh\|ryP	NF;GSYtUSU6JRWK=
NCI-H1437	M{HhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fxSmlEPTB;MD62NFYyQSEQvF2=	M{jQSXNCVkeHUh?=
KGN	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[xb2kzUUN3ME2wMlYyODR7IN88US=>	M1XuRnNCVkeHUh?=
NCI-H2452	NXK5NoFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\LTWM2OD1yLk[xPVE4KM7:TR?=	NV\ZSVZ[W0GQR1XS
BFTC-905	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwNkKxNlYh\|ryP	NWPvVIkyW0GQR1XS
CAMA-1	M4rQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\6RpJKSzVyPUCuOlIyPTJizszN	MXTTRW5ITVJ?
SK-NEP-1	M4LaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGP3XoNKSzVyPUCuOlI2ODJizszN	Mn3GV2FPT0WU
NCI-H522	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlWwTWM2OD1yLk[yPVkzKM7:TR?=	MlThV2FPT0WU
SW1710	NF;4dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX4So1CUUN3ME2wMlY{OTZ5IN88US=>	NHfMUVhUSU6JRWK=
RVH-421	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwNkO2N\|kh\|ryP	MX;TRW5ITVJ?
SK-MEL-2	NUPnc2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoSzTWM2OD1yLk[0NVU{KM7:TR?=	MU\TRW5ITVJ?
KYSE-150	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7nWmlKSzVyPUCuOlYyQDZizszN	MlnXV2FPT0WU
MOLT-13	NXzVcZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwNk[1N\|ch\|ryP	NIqwSlFUSU6JRWK=
SK-OV-3	NF3FNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwNkexPFch\|ryP	Ml7KV2FPT0WU
IGROV-1	M3nGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwNke0OUDPxE1?	M3Wx[HNCVkeHUh?=
MOLT-4	NWmyWIZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonLTWM2OD1yLk[3Olg6KM7:TR?=	Mnz0V2FPT0WU
MEL-HO	NHvyVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nzbGlEPTB;MD62O\|c2OiEQvF2=	MWnTRW5ITVJ?
MDA-MB-157	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHUcZM1UUN3ME2wMlY4QDFizszN	MlTlV2FPT0WU
MN-60	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfvR41KSzVyPUCuOlc5PDZizszN	NEDCSHVUSU6JRWK=
EFO-27	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq0TWM2OD1yLk[3PVc6KM7:TR?=	MUHTRW5ITVJ?
HO-1-N-1	NGC1N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W2cGlEPTB;MD62PFA3PCEQvF2=	NFPsWmNUSU6JRWK=
TE-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\sTWM2OD1yLk[4OFA2KM7:TR?=	NF[zfJRUSU6JRWK=
EW-22	M{\KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjsTWM2OD1yLk[4OFQ1KM7:TR?=	NF7HRoVUSU6JRWK=
SW982	NEnVWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz0bYtKSzVyPUCuOlg2ODFizszN	MnvhV2FPT0WU
SF295	NFvOWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvNSWlPUUN3ME2wMlY5PTB5IN88US=>	MWPTRW5ITVJ?
WM-115	NULKXYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;yN2lEPTB;MD62PFkzPCEQvF2=	NXryfHV[W0GQR1XS
COLO-800	NYXZRolrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTuTWM2OD1yLk[5PFE{KM7:TR?=	NXP1Xo5VW0GQR1XS
NTERA-S-cl-D1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTBwN{CwOlMh\|ryP	NHf1bG5USU6JRWK=
NCI-H1648	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[3ZmlEPTB;MD63NFE4OyEQvF2=	M1S2N3NCVkeHUh?=
NB5	NUTnVJhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC1TWM2OD1yLkewN\|E6KM7:TR?=	NW\zboNVW0GQR1XS
ATN-1	NEXydI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwN{C1PUDPxE1?	M33oNnNCVkeHUh?=
NUGC-3	M1\WT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLETWM2OD1yLkewOlkyKM7:TR?=	MmfUV2FPT0WU
22RV1	NVTaS\|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXDVWpuUUN3ME2wMlcxPzF5IN88US=>	Ml7jV2FPT0WU
8305C	NHrkSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jE[WlEPTB;MD63NFc2PSEQvF2=	NELhXoJUSU6JRWK=
EFM-19	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnntTWM2OD1yLkewPFQ4KM7:TR?=	Ml7WV2FPT0WU
PC-3	NUf1b2lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Di[GlEPTB;MD63NlI{KM7:TR?=	MXfTRW5ITVJ?
C32	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDISodKSzVyPUCuO\|I1QDRizszN	MVHTRW5ITVJ?
MC-IXC	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLWWYZKSzVyPUCuO\|I4OThizszN	NHX6flNUSU6JRWK=
OMC-1	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwN{K3N\|gh\|ryP	NEnDO3RUSU6JRWK=
HTC-C3	NXHZcZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDLdG5kUUN3ME2wMlc{OTd{IN88US=>	Ml3pV2FPT0WU
RPMI-7951	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV6wdGxkUUN3ME2wMlc{PTN\|IN88US=>	M4PYRXNCVkeHUh?=
AsPC-1	M4nvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrUZZRnUUN3ME2wMlc{Pzl3IN88US=>	M2K1N3NCVkeHUh?=
CAKI-1	NEPwb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrhT4dsUUN3ME2wMlc1PjJ7IN88US=>	M2DrU3NCVkeHUh?=
MHH-PREB-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jScmlEPTB;MD63OFc{PiEQvF2=	MoLaV2FPT0WU
HLE	NY\YdY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwN{S4OFQh\|ryP	NXLzcmxpW0GQR1XS
A375	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLFRXNKSzVyPUCuO\|UyQTNizszN	M1O1bXNCVkeHUh?=
RS4-11	NFTvdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jwV2lEPTB;MD63OVk1OyEQvF2=	NVX3eVFkW0GQR1XS
U-2-OS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2P5XGlEPTB;MD63OVk4KM7:TR?=	MnfaV2FPT0WU
NCI-H747	M3P2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XmfGlEPTB;MD63OVk6OSEQvF2=	M3;5bnNCVkeHUh?=
NCI-H1623	NYjGfVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnReY9KSzVyPUCuO\|YzPjFizszN	M2DpWXNCVkeHUh?=
DMS-273	NILvfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nlcGlEPTB;MD63OlkzOiEQvF2=	NVHDTZdKW0GQR1XS
PSN1	M{HQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4G1R2lEPTB;MD63O\|A2PyEQvF2=	NWL0[4pNW0GQR1XS
LU-99A	NHL0TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M133NGlEPTB;MD63O\|Y1QSEQvF2=	NEnCXWVUSU6JRWK=
CAL-12T	NI\IOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PMOGlEPTB;MD63PFAzQSEQvF2=	NHfNd4xUSU6JRWK=
KYSE-140	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXQTWM2OD1yLke4NVY5KM7:TR?=	NXP6Z\|NUW0GQR1XS
VMRC-RCZ	NUjzNpdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwN{i0PFIh\|ryP	NGTOb29USU6JRWK=
Ca9-22	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfGTWM2OD1yLke4O\|M3KM7:TR?=	NXPjXIZ{W0GQR1XS
NCI-H1563	NHnaPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7pTWM2OD1yLke4PVI3KM7:TR?=	NGPDe\|FUSU6JRWK=
NCI-H650	NHq1TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PkNGlEPTB;MD63PVE1PCEQvF2=	NFrzNZVUSU6JRWK=
DOHH-2	NXHzcJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPQblNlUUN3ME2wMlc6OzNizszN	NWHSXIREW0GQR1XS
OE33	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwN{m5NVQh\|ryP	NV23S3lkW0GQR1XS
CAL-62	NIDzfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\qNZNvUUN3ME2wMlc6QTJ2IN88US=>	MWXTRW5ITVJ?
NCI-H1770	M3j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTBwOECyNUDPxE1?	M{ezZXNCVkeHUh?=
SN12C	M1K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzrTWM2OD1yLkiwOlY5KM7:TR?=	M4jteXNCVkeHUh?=
HPAF-II	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\PTWM2OD1yLkiwO\|k1KM7:TR?=	MknHV2FPT0WU
SNU-423	NYPyTW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPsTWM2OD1yLkixOFIzKM7:TR?=	MmTSV2FPT0WU
A704	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHQTWM2OD1yLkixO\|k5KM7:TR?=	Mki3V2FPT0WU
OVCAR-4	M4XXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwOEG5NVEh\|ryP	Mm[2V2FPT0WU
NCI-H2347	NH\0O4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnwTWM2OD1yLkiyOFAyKM7:TR?=	MoHiV2FPT0WU
OCUB-M	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{P2bmlEPTB;MD64NlY4PSEQvF2=	NX;W[5BqW0GQR1XS
KYSE-450	NW\jUmFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfXTWM2OD1yLkiyO\|I2KM7:TR?=	MXXTRW5ITVJ?
PFSK-1	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TsVmlEPTB;MD64N\|A{QSEQvF2=	MkjZV2FPT0WU
A431	NYf3VIVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS1TWM2OD1yLkizNVE3KM7:TR?=	M1[yXHNCVkeHUh?=
MHH-ES-1	NEnvNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jGN2lEPTB;MD64N\|Q2PyEQvF2=	NHz4d49USU6JRWK=
HD-MY-Z	NWXkOXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXtSWFKSzVyPUCuPFQxQTJizszN	NFmxXnZUSU6JRWK=
RT-112	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTBwOES5N\|ch\|ryP	NUDYNJkzW0GQR1XS
KU-19-19	NGryeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTBwOEWxNlEh\|ryP	NGrJOYtUSU6JRWK=
HCC1569	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDuXWNKSzVyPUCuPFUzODdizszN	NWjhPZJCW0GQR1XS
RPMI-8866	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzOVpBFUUN3ME2wMlg2QDJ{IN88US=>	MYrTRW5ITVJ?
CAL-120	M3jOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTxTWM2OD1yLki2NFQyKM7:TR?=	NGDETppUSU6JRWK=
CAL-33	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe2Om9KSzVyPUCuPFY1QTVizszN	NWjpT4pwW0GQR1XS
RKO	NEjBZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfzTWM2OD1yLki2PFE4KM7:TR?=	Mn2xV2FPT0WU
HCC1419	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUixWIZuUUN3ME2wMlg3QTJ6IN88US=>	NEXKVZdUSU6JRWK=
CP50-MEL-B	M4O3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwOEizPFQh\|ryP	Moj2V2FPT0WU
BPH-1	NUX4b3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPObVRKSzVyPUCuPFg{QTVizszN	MX3TRW5ITVJ?
SF126	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELzcmZKSzVyPUCuPFg4OTRizszN	MmO5V2FPT0WU
BHY	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTBwOEi3N\|Qh\|ryP	NHP5[JFUSU6JRWK=
BxPC-3	NH\yPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHyTWM2OD1yLki4PFM{KM7:TR?=	MorOV2FPT0WU
ETK-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXNb\|lKSzVyPUCuPFk{PzJizszN	M3rDUnNCVkeHUh?=
NCI-H1573	M1L5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwOUCyNlkh\|ryP	NXfiR3dYW0GQR1XS
C-33-A	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MliwTWM2OD1yLkmwOFQzKM7:TR?=	MYHTRW5ITVJ?
UACC-893	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7mNZlKSzVyPUCuPVI5PTVizszN	NV3rXGp6W0GQR1XS
RXF393	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDveG1KSzVyPUCuPVI5QTdizszN	NF;V[pNUSU6JRWK=
MIA-PaCa-2	M2m3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjNdYVKSzVyPUCuPVI6OjJizszN	NInlPI1USU6JRWK=
HCC1806	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\ZTWM2OD1yLkmzNlU3KM7:TR?=	Mn:5V2FPT0WU
DMS-114	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[yUVFKSzVyPUCuPVM3PzdizszN	MlP4V2FPT0WU
MOLT-16	NH;QdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwOUO4OFUh\|ryP	M4izenNCVkeHUh?=
ACN	NIXRc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L4R2lEPTB;MD65OFI4PyEQvF2=	Mn\vV2FPT0WU
SNU-449	M{HIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1eyW2lEPTB;MD65OVkzPCEQvF2=	NYTlfmwxW0GQR1XS
A427	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj5dW1KSzVyPUCuPVYyQThizszN	NXzBfod2W0GQR1XS
DEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fEb2lEPTB;MD65Olc4OyEQvF2=	NYjQV4xIW0GQR1XS
NCI-H1792	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHlWoFKSzVyPUCuPVcyODFizszN	NI[4d3RUSU6JRWK=
A2058	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwOUezOkDPxE1?	NELDT\|NUSU6JRWK=
SW13	NXvudWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO0UmFZUUN3ME2wMlk5Ozl{IN88US=>	NVLMVGtlW0GQR1XS
T98G	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHQWFN5UUN3ME2xMlAyOzZ2IN88US=>	MWHTRW5ITVJ?
LU-134-A	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnGzTWM2OD1zLkCyOlc2KM7:TR?=	MmrhV2FPT0WU
GI-ME-N	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTN[4Y1UUN3ME2xMlAzQDJ5IN88US=>	MnWxV2FPT0WU
D-423MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEi4c3RKSzVyPUGuNFI6PjNizszN	NITtV4FUSU6JRWK=
PANC-03-27	M1nDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TVSmlEPTB;MT6wN\|E1OSEQvF2=	NW\ofm5{W0GQR1XS
P12-ICHIKAWA	NYOxVVI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTLeWRKSzVyPUGuNFM1ODZizszN	M4\JOXNCVkeHUh?=
SCH	M13mSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFwMEO0OUDPxE1?	NX3Ve\|RlW0GQR1XS
D-566MG	NETjToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3WR5FKSzVyPUGuNFY4OjZizszN	MWnTRW5ITVJ?
OS-RC-2	M1P4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXmU2E3UUN3ME2xMlA4QTRizszN	M1\yU3NCVkeHUh?=
KOSC-2	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTFwMEiwNlEh\|ryP	MUHTRW5ITVJ?
SH-4	M4XsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV:3TWFjUUN3ME2xMlA5PDNzIN88US=>	NUmzfY1KW0GQR1XS
786-0	NEfOO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HNWGlEPTB;MT6wPFk{PCEQvF2=	MlnXV2FPT0WU
Mewo	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjSSZI1UUN3ME2xMlA6OjR6IN88US=>	NULheGQ4W0GQR1XS
AGS	M4TVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzvTWM2OD1zLkC5OFU6KM7:TR?=	NI\3SnpUSU6JRWK=
Daoy	NHG2d3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\sfI9HUUN3ME2xMlA6PjJ6IN88US=>	NXHPVItyW0GQR1XS
SW48	NVjF[W1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13YS2lEPTB;MT6xNFkyOSEQvF2=	NGHHTVJUSU6JRWK=
KYSE-180	M{DUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rURmlEPTB;MT6xNVAzOSEQvF2=	NEfJR2pUSU6JRWK=
NH-12	NIL3WWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LTSWlEPTB;MT6xNVI{PyEQvF2=	NUXYZ\|FWW0GQR1XS
BE-13	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe3TWM2OD1zLkGxO\|U6KM7:TR?=	MUfTRW5ITVJ?
ES3	NXewNnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XlSWlEPTB;MT6xN\|E4OSEQvF2=	MXjTRW5ITVJ?
NCI-H1092	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fNdWlEPTB;MT6xN\|Qh\|ryP	MlvuV2FPT0WU
NCI-H1755	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjoS25KSzVyPUGuNVM6PDFizszN	MYHTRW5ITVJ?
EKVX	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFwMUSwNFEh\|ryP	M1XXT3NCVkeHUh?=
NB13	NUjiW291T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIG4PYpKSzVyPUGuNVQ1PSEQvF2=	M4PwWHNCVkeHUh?=
NCI-H2405	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFwMUS1O\|Qh\|ryP	M4XrcXNCVkeHUh?=
LS-411N	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XhRmlEPTB;MT6xOVAyPyEQvF2=	NV;uW\|RWW0GQR1XS
MDA-MB-453	NXvlNWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHS[lZKSzVyPUGuNVU3OjRizszN	M1K5PXNCVkeHUh?=
SCC-15	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwMU[5OVYh\|ryP	NXfNbnJXW0GQR1XS
C2BBe1	NGW3PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTFwMUewOVYh\|ryP	MkfUV2FPT0WU
HT-144	NFrQXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjsVG14UUN3ME2xMlE4ODdizszN	M3\sSXNCVkeHUh?=
HEC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvUTWM2OD1zLkG3OlI4KM7:TR?=	NIPpdZNUSU6JRWK=
HCE-T	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLtTWM2OD1zLkG3PVg{KM7:TR?=	Ml3wV2FPT0WU
IST-MEL1	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfyOINKSzVyPUGuNVkxQDJizszN	MVXTRW5ITVJ?
Detroit562	M{jj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLRTWM2OD1zLkG5OFM6KM7:TR?=	M4DuPHNCVkeHUh?=
A4-Fuk	NUDKNmNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWG4[3ByUUN3ME2xMlIxPDRzIN88US=>	Moe0V2FPT0WU
HDLM-2	NEHOUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j5XmlEPTB;MT6yNVMzPiEQvF2=	M{m0OHNCVkeHUh?=
MKN7	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHoZpFXUUN3ME2xMlIyPzB{IN88US=>	NFGxZ3FUSU6JRWK=
MDA-MB-415	M3\5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe2XmRKSzVyPUGuNlE4ODJizszN	NXnwb4JuW0GQR1XS
BT-20	NGfPdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37OUmlEPTB;MT6yNlQ1PCEQvF2=	NGnp[pFUSU6JRWK=
NCI-H2030	NYDaWplkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEThRWZKSzVyPUGuNlQyODZizszN	MVXTRW5ITVJ?
LS-123	M4H4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrzOWlKSzVyPUGuNlQ4PTNizszN	NETseGxUSU6JRWK=
SK-MEL-3	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXLTWM2OD1zLkK0O\|c3KM7:TR?=	NUSxSI45W0GQR1XS
KS-1	NIXLeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX2Tpp4UUN3ME2xMlI2OTdzIN88US=>	MWrTRW5ITVJ?
LU-65	M{\PU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\JSmlEPTB;MT6yOVYxPiEQvF2=	Mk[zV2FPT0WU
NCI-H596	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrXTWM2OD1zLkK1PVI6KM7:TR?=	M4Pw[HNCVkeHUh?=
KYSE-410	M3\DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwMkewNVQh\|ryP	MnfxV2FPT0WU
NCI-H2228	M2\Nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zyT2lEPTB;MT6yO\|E3PyEQvF2=	NWPoelFYW0GQR1XS
LN-405	NU\Nc5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[wTWM2OD1zLkK4NFIyKM7:TR?=	M4W2e3NCVkeHUh?=
8505C	NYLZd497T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnaTWM2OD1zLkK4PFI{KM7:TR?=	MnzEV2FPT0WU
BFTC-909	NGr0UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2OwPWlEPTB;MT6yPVQ{PCEQvF2=	M3TzZXNCVkeHUh?=
OC-314	M3fPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHGTWM2OD1zLkK5PVI6KM7:TR?=	NYG3ZmF4W0GQR1XS
NMC-G1	M4nLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHGwZ2FKSzVyPUGuN\|EyOzVizszN	Mmf2V2FPT0WU
SKG-IIIa	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfwU5hKSzVyPUGuN\|E1OjhizszN	NWPiToRmW0GQR1XS
GAK	NH7sPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfoWWlvUUN3ME2xMlMyQDV6IN88US=>	MnziV2FPT0WU
D-263MG	M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFwM{K2OFEh\|ryP	NUHTZ2N4W0GQR1XS
NCI-H446	NH:zS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDETWM2OD1zLkOyPVAzKM7:TR?=	NHLObFFUSU6JRWK=
TGBC1TKB	NIH0e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWOxeHVvUUN3ME2xMlMzQTl6IN88US=>	NWjhTmpLW0GQR1XS
GCT	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnnR4VYUUN3ME2xMlM1OzR3IN88US=>	NIjZe5JUSU6JRWK=
COR-L23	NWf4OZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwM{S4OFUh\|ryP	NV7zSHoyW0GQR1XS
TK10	NXzlOIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHX5S5VKSzVyPUGuN\|U4QTdizszN	NHr3Z\|hUSU6JRWK=
ES6	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwM{[zO\|Yh\|ryP	NVm4cZVYW0GQR1XS
SW1088	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPEdGtIUUN3ME2xMlM3PjF{IN88US=>	NILHVXpUSU6JRWK=
AM-38	NFzE[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHf6dFJKSzVyPUGuN\|cyQTlizszN	MUXTRW5ITVJ?
CHP-134	NYrBSHVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwM{e4OFQh\|ryP	NUT6PVd3W0GQR1XS
SW872	NVPNSmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mme5TWM2OD1zLkO4OVU2KM7:TR?=	M{fjZnNCVkeHUh?=
LB831-BLC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\vTWM2OD1zLkO5NFY4KM7:TR?=	NYO5SVZIW0GQR1XS
TE-12	M{LO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnvVY1xUUN3ME2xMlQxPjBzIN88US=>	MYfTRW5ITVJ?
LCLC-97TM1	NH7JbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rEemlEPTB;MT60NVA1PiEQvF2=	M1q5[3NCVkeHUh?=
HCT-116	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2K2RmlEPTB;MT60Nlg2PCEQvF2=	NFT6dHVUSU6JRWK=
ALL-PO	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHn3cJVKSzVyPUGuOFM4PzRizszN	Mk\xV2FPT0WU
EW-16	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHWdYU2UUN3ME2xMlQ{QDR{IN88US=>	MXHTRW5ITVJ?
NCI-H661	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HGcGlEPTB;MT60OFc4PSEQvF2=	NFvL[4hUSU6JRWK=
TE-8	M4HEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTFwNEW1OkDPxE1?	MW\TRW5ITVJ?
TCCSUP	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfEOFY6UUN3ME2xMlQ3QTZizszN	NFHDRnpUSU6JRWK=
SW1990	M37lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnsbmhoUUN3ME2xMlQ4PTN\|IN88US=>	MlfJV2FPT0WU
UM-UC-3	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfSOYRKSzVyPUGuOFc3PzVizszN	NEnsfFNUSU6JRWK=
HuP-T4	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\yTWM2OD1zLkS4OlA4KM7:TR?=	M3G3XnNCVkeHUh?=
NCI-H1299	NIfUXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fwfWlEPTB;MT61NFA5PiEQvF2=	MWXTRW5ITVJ?
RO82-W-1	NGrz[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHGS2tKSzVyPUGuOVIxQDFizszN	M1\tOXNCVkeHUh?=
Becker	NWfkd5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTySVV[UUN3ME2xMlUzOTh5IN88US=>	Mk\0V2FPT0WU
SNU-387	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfYVW42UUN3ME2xMlUzOjRzIN88US=>	Mm[2V2FPT0WU
CAL-85-1	NEjQUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTFTnl3UUN3ME2xMlUzPTl7IN88US=>	M{TNXnNCVkeHUh?=
647-V	NIH1S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3YTWM2OD1zLkWzPFgh\|ryP	NV7KWpRsW0GQR1XS
SBC-5	NIfiR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTFwNUS1PVMh\|ryP	MX\TRW5ITVJ?
NCI-H23	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFwNUW3NVQh\|ryP	MWfTRW5ITVJ?
CGTH-W-1	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fpRWlEPTB;MT61OVgyQSEQvF2=	M2jsdHNCVkeHUh?=
SK-N-FI	NV\2PVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zwXGlEPTB;MT61OVkxQCEQvF2=	NHviUpNUSU6JRWK=
KM-H2	NGnHbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInMR5dKSzVyPUGuOVY1PzRizszN	NFLUNWFUSU6JRWK=
KY821	NYLzeYNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vuNGlEPTB;MT61OlYyPyEQvF2=	MWrTRW5ITVJ?
RH-1	NVrMc4w3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1H2U2lEPTB;MT61Olc3OiEQvF2=	NGn1S4dUSU6JRWK=
KYSE-270	MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTFwNUe0NlMh\|ryP	NFLwVphUSU6JRWK=
SF539	M2XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Gz[WlEPTB;MT61O\|k3QSEQvF2=	MoWxV2FPT0WU
JEG-3	NHTle3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVeyNVVLUUN3ME2xMlU5ODl2IN88US=>	NVezNYVqW0GQR1XS
SCC-25	NGfFbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHoOHI4UUN3ME2xMlU5PDN{IN88US=>	MnPVV2FPT0WU
SW1573	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3CcYQzUUN3ME2xMlYxOTV6IN88US=>	NHPFXW9USU6JRWK=
EW-1	NHPvd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjtcppKSzVyPUGuOlE{PTFizszN	NYf6SW0{W0GQR1XS
YKG-1	M2rwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPiUI5{UUN3ME2xMlYyPDN6IN88US=>	NXzGW4xQW0GQR1XS
EW-11	NV[yR2ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3VfnREUUN3ME2xMlYyPzRzIN88US=>	Mlm2V2FPT0WU
DJM-1	NIn6VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzmWY8yUUN3ME2xMlYyQDJ3IN88US=>	NYjtSIlpW0GQR1XS
Calu-3	NVm1TWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwNkWyNVMh\|ryP	M4D1[nNCVkeHUh?=
HT-3	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFwNkW2OkDPxE1?	NH3UbJpUSU6JRWK=
NCI-H69	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHuTWM2OD1zLk[3N\|Q{KM7:TR?=	MlzZV2FPT0WU
NCI-H2126	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2O5c2lEPTB;MT62O\|c6PyEQvF2=	M2jvN3NCVkeHUh?=
RPMI-2650	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHsfINGUUN3ME2xMlY5OzF5IN88US=>	NWfoW285W0GQR1XS
TE-6	M{PWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTFwN{C4O\|Qh\|ryP	MkO1V2FPT0WU
MDA-MB-231	NXzB[WdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;oSW1zUUN3ME2xMlcyQTl\|IN88US=>	MW\TRW5ITVJ?
A2780	NWnJemd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n2d2lEPTB;MT63NlIxPyEQvF2=	NHL2WXFUSU6JRWK=
GOTO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XMZmlEPTB;MT63N\|U3KM7:TR?=	Mo\OV2FPT0WU
KYSE-70	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTFwN{S0OFIh\|ryP	M1vxPHNCVkeHUh?=
GMS-10	NU\ucplCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwN{S2OlIh\|ryP	M3LoWXNCVkeHUh?=
CaR-1	M2LSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTFwN{S4NVIh\|ryP	M1zOXnNCVkeHUh?=
SW900	M4WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TKRWlEPTB;MT63OFk6OyEQvF2=	Mkm2V2FPT0WU
BB49-HNC	NX2w[441T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[wbodPUUN3ME2xMlc2OTZ6IN88US=>	NHnCbWZUSU6JRWK=
SNB75	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;wUXVTUUN3ME2xMlc2PDl{IN88US=>	NGnibHBUSU6JRWK=
SK-PN-DW	M4HlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwN{W2PFIh\|ryP	NGmxS2dUSU6JRWK=
5637	NWXEco95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;udYUxUUN3ME2xMlc4OjZ6IN88US=>	M1P5cnNCVkeHUh?=
BT-474	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7UTWM2OD1zLke4NVcyKM7:TR?=	MVfTRW5ITVJ?
KM12	M3rucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnizTWM2OD1zLke5O\|QyKM7:TR?=	NX3tPVl{W0GQR1XS
COLO-680N	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGG5eW5KSzVyPUGuPFI{QDFizszN	MU\TRW5ITVJ?
Saos-2	NWPsRWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXVTWM2OD1zLkiyOFQ2KM7:TR?=	MnH6V2FPT0WU
CAL-54	NGPxb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWiyUlhZUUN3ME2xMlg{OzF\|IN88US=>	M4ThbnNCVkeHUh?=
U-118-MG	M1LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[xVmNYUUN3ME2xMlg1PjJ{IN88US=>	MYTTRW5ITVJ?
TGBC24TKB	NIO5XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu2V5FNUUN3ME2xMlg2PTBzIN88US=>	M4fVW3NCVkeHUh?=
NCI-H2052	M3rL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTFwOE[0NUDPxE1?	M3r2N3NCVkeHUh?=
BB30-HNC	M{PuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFwOE[0OlIh\|ryP	NWPQOFQ6W0GQR1XS
KNS-81-FD	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\qbWlEPTB;MT64PVE3PSEQvF2=	MVvTRW5ITVJ?
HN	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD4TWM2OD1zLki5OVQ2KM7:TR?=	MUfTRW5ITVJ?
ACHN	NFrTPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfwVYhxUUN3ME2xMlkxPzh4IN88US=>	M{XyOHNCVkeHUh?=
HSC-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn0TYJKSzVyPUGuPVExQTZizszN	NIX0S5JUSU6JRWK=
HCC2998	M1HQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnT0TWM2OD1zLkmzN\|I2KM7:TR?=	NYfHfm5yW0GQR1XS
HEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwOUSxPFQh\|ryP	M{nZXXNCVkeHUh?=
SW684	NWLGTlJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PZcGlEPTB;MT65O\|M4OSEQvF2=	MVnTRW5ITVJ?
NCI-H1693	M3Hq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYC4[Yh3UUN3ME2xMlk5ODh4IN88US=>	MmDSV2FPT0WU
8-MG-BA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DVTmlEPTB;MT65PFIyKM7:TR?=	MULTRW5ITVJ?
OVCAR-8	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTETWM2OD1{LkCwNlk2KM7:TR?=	NIPqOYlUSU6JRWK=
DSH1	M3XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoexTWM2OD1{LkCxO\|c1KM7:TR?=	NGjiRYtUSU6JRWK=
KYSE-520	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJwMEKwOFkh\|ryP	NHPaPXpUSU6JRWK=
GB-1	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoG3TWM2OD1{LkCyOVc4KM7:TR?=	NF;FfJVUSU6JRWK=
RCC10RGB	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGj4PGhKSzVyPUKuNFQ5PzFizszN	MmfrV2FPT0WU
SW954	NXzQTIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\jTWM2OD1{LkC1NFM3KM7:TR?=	NX7p[5J{W0GQR1XS
IST-MES1	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrD[HRQUUN3ME2yMlA2PTZ6IN88US=>	NFHmRVlUSU6JRWK=
AU565	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PURWlEPTB;Mj6wOVkxPSEQvF2=	MonxV2FPT0WU
CW-2	NYraco1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jxN2lEPTB;Mj6wOlg4PSEQvF2=	M2LsS3NCVkeHUh?=
TE-1	NXHxRlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DYdmlEPTB;Mj6wPVM4PyEQvF2=	NVzPenlOW0GQR1XS
KP-4	M4TPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2eyZmlEPTB;Mj6xNFMyOiEQvF2=	M2fWfnNCVkeHUh?=
SNU-C2B	M33nOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7DTWM2OD1{LkGwPFI{KM7:TR?=	MnzXV2FPT0WU
NCI-H1395	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJwMUC5PFYh\|ryP	MmLsV2FPT0WU
CAS-1	M3vMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrSbVBKSzVyPUKuNVE2PDZizszN	MlLiV2FPT0WU
NCI-H1155	NI\HUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LKeWlEPTB;Mj6yNlY6KM7:TR?=	NF:0XItUSU6JRWK=
SK-MEL-1	NGLZc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJwMkixPFEh\|ryP	M4eyTHNCVkeHUh?=
KINGS-1	NWrufm53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTJwM{CwPFgh\|ryP	M4XWfXNCVkeHUh?=
ESS-1	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjyRWZbUUN3ME2yMlMxPTFizszN	MX3TRW5ITVJ?
PANC-10-05	NXrye3JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPYSFNKSzVyPUKuN\|cxOjRizszN	Mn;GV2FPT0WU
HT-1376	NIfkRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJwM{i3NFgh\|ryP	NIfjdWtUSU6JRWK=
LS-513	M4qwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M161UWlEPTB;Mj6zPFg4PCEQvF2=	NXGzXVVDW0GQR1XS
KNS-42	NFO0fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LQdmlEPTB;Mj6zPVExPSEQvF2=	NWfEV4cyW0GQR1XS
639-V	M12wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfDTnFbUUN3ME2yMlQzPzV6IN88US=>	NGfIWGlUSU6JRWK=
SJRH30	M2X4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUexNIpqUUN3ME2yMlQ2OTZzIN88US=>	NHTSeYtUSU6JRWK=
SW1783	M4nnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;OTWM2OD1{LkS3NFc5KM7:TR?=	NYe0VZViW0GQR1XS
NB6	M{KzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:1S2lEPTB;Mj60PFI5KM7:TR?=	Mn\OV2FPT0WU
SK-MEL-30	NG\kSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zwT2lEPTB;Mj60PFg{KM7:TR?=	M{LYXXNCVkeHUh?=
HCE-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fFV2lEPTB;Mj60PVQxOiEQvF2=	NILuV2NUSU6JRWK=
NB10	NUfKcW9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfHcolQUUN3ME2yMlQ6PDJ7IN88US=>	MlHzV2FPT0WU
H-EMC-SS	NHfiXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJwNUS2OUDPxE1?	M{jne3NCVkeHUh?=
SK-HEP-1	NYDhNHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYK0WGxMUUN3ME2yMlU2OjN4IN88US=>	M1\OWHNCVkeHUh?=
HCC1395	M376c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1q1UGlEPTB;Mj61OVY2PSEQvF2=	NIqzU4tUSU6JRWK=
HuCCT1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7GTWM2OD1{LkW2N\|kh\|ryP	MXLTRW5ITVJ?
SiHa	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjuTWM2OD1{LkW4O\|E6KM7:TR?=	NWO3OopQW0GQR1XS
EFO-21	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrmSIxKSzVyPUKuOVg4PjRizszN	MlK0V2FPT0WU
NCI-H1666	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTJwNUmwO\|Yh\|ryP	NHvN[JFUSU6JRWK=
UMC-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW2TWxVUUN3ME2yMlU6QDZ6IN88US=>	NVHiZlBzW0GQR1XS
COLO-679	NELadlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XpUWlEPTB;Mj62NVI{OyEQvF2=	M4i0TnNCVkeHUh?=
A388	NXThRpRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlqzTWM2OD1{Lk[1NlU{KM7:TR?=	M4nMS3NCVkeHUh?=
LB2518-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfIR\|A1UUN3ME2yMlY2PDB6IN88US=>	NWXhNJJHW0GQR1XS
EW-13	NHy3TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoToTWM2OD1{Lk[4O\|Y5KM7:TR?=	MUDTRW5ITVJ?
MLMA	NWeyV5VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILlZ5VKSzVyPUKuOlg5PTZizszN	M2X6cXNCVkeHUh?=
HOP-92	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJwN{CxNUDPxE1?	MkjjV2FPT0WU
NOMO-1	M1LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTJwN{G0OFIh\|ryP	M1TzeHNCVkeHUh?=
NCI-H810	NG\S[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXsTWM2OD1{LkeyNVk5KM7:TR?=	M162UHNCVkeHUh?=
769-P	NVrsN3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XncWlEPTB;Mj63NlI5KM7:TR?=	MXTTRW5ITVJ?
SAS	NXK0d4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zZemlEPTB;Mj63OlUh\|ryP	M3vrTnNCVkeHUh?=
M059J	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\XTWM2OD1{Lke4N\|E5KM7:TR?=	M2K3b3NCVkeHUh?=
RD	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFm3UFdKSzVyPUKuO\|k1PzFizszN	NYjhbGlRW0GQR1XS
GT3TKB	NH;mdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfUTWM2OD1{LkizOFM{KM7:TR?=	MX;TRW5ITVJ?
MZ7-mel	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[5WmpKSzVyPUKuPFY2ODJizszN	MXnTRW5ITVJ?
KYSE-510	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJwOEm1NFQh\|ryP	NInudZpUSU6JRWK=
NCI-N87	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjDcmZKSzVyPUKuPVE5ODdizszN	MV\TRW5ITVJ?
MKN1	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P4eGlEPTB;Mz6wNFE3OyEQvF2=	MnHxV2FPT0WU
NCI-H2170	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXqVW9kUUN3ME2zMlAxPDVzIN88US=>	MVrTRW5ITVJ?
OVCAR-3	M{LmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTNwMEKxNVUh\|ryP	M3nN[XNCVkeHUh?=
KLE	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rTUmlEPTB;Mz6wOlgyOiEQvF2=	M{DKe3NCVkeHUh?=
LB771-HNC	NHHyOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIP1c3hKSzVyPUOuNFk{PDNizszN	MmPFV2FPT0WU
MC116	M{TjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmC0TWM2OD1\|LkGxNVEzKM7:TR?=	NFjwflVUSU6JRWK=
SCC-9	NXnDc2NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjzRnBlUUN3ME2zMlEyOzZ4IN88US=>	NFrSVWRUSU6JRWK=
U031	MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK3VmhKSzVyPUOuNVI1OjNizszN	MYTTRW5ITVJ?
LCLC-103H	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nj[2lEPTB;Mz6yN\|g6PCEQvF2=	NYDvXlRMW0GQR1XS
U-266	NFKyTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLa[I1lUUN3ME2zMlI4PjN\|IN88US=>	MmrkV2FPT0WU
JVM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTNwM{KxOlQh\|ryP	MWrTRW5ITVJ?
UACC-257	NG[zRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvrR5dFUUN3ME2zMlQ3PDNzIN88US=>	MlTLV2FPT0WU
LB996-RCC	NXzO[481T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DUXmlEPTB;Mz60OlUxOiEQvF2=	NX;sc\|dFW0GQR1XS
BT-549	NFzZXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTNwNUCyNFkh\|ryP	NVvy[HZ4W0GQR1XS
NCI-H526	NYXMXY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFGzOVNKSzVyPUOuOVQyPThizszN	M4fLU3NCVkeHUh?=
RH-18	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17IUmlEPTB;Mz62NVc6QCEQvF2=	M1fhUXNCVkeHUh?=
SW626	NGLifnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHP5d3FKSzVyPUOuO\|EyOjhizszN	M2j1NnNCVkeHUh?=
SK-N-AS	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnG5TWM2OD1\|LkezNlQ4KM7:TR?=	M{CwdXNCVkeHUh?=
IGR-1	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HOT2lEPTB;Mz63OFI1QCEQvF2=	NX7xRoVOW0GQR1XS
NCI-H2291	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTNwN{WzN\|Yh\|ryP	NGTjbolUSU6JRWK=
NCI-H441	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37zO2lEPTB;Mz64NlQ{OyEQvF2=	MWDTRW5ITVJ?
D-247MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f1eWlEPTB;Mz64OlA{OSEQvF2=	NUXDe\|NNW0GQR1XS
COLO-320-HSR	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4eyd2lEPTB;Mz65NVI4OSEQvF2=	MnnwV2FPT0WU
A253	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDUd4xnUUN3ME2zMlkyPDN4IN88US=>	MX;TRW5ITVJ?
HT55	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f0SmlEPTB;Mz65NVc4OyEQvF2=	MU\TRW5ITVJ?
MZ1-PC	NXHVenE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\qPGlEPTB;Mz65OVg3PCEQvF2=	MnTXV2FPT0WU
RERF-LC-MS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTNwOU[1NlUh\|ryP	NEX2[5pUSU6JRWK=
SF268	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C4eWlEPTB;ND6xNlg5OSEQvF2=	MYrTRW5ITVJ?
RMG-I	NHPXNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTWRmJKSzVyPUSuNlE1PTRizszN	MWXTRW5ITVJ?
CFPAC-1	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HXXWlEPTB;ND6yNVY5PSEQvF2=	M1jGTnNCVkeHUh?=
S-117	NWHSOY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnlZlI3UUN3ME20MlIzODJ2IN88US=>	NEHYV4dUSU6JRWK=
NCI-H2122	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkixTWM2OD12LkOwPVMyKM7:TR?=	MVfTRW5ITVJ?
J82	M2TQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzjXHBxUUN3ME20MlM{PDRzIN88US=>	NEDFN2lUSU6JRWK=
CAL-72	M{TGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnI[\|JKSzVyPUSuN\|U1PzdizszN	MXrTRW5ITVJ?
GP5d	M1H1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfUTWM2OD12LkSxNlk5KM7:TR?=	MU\TRW5ITVJ?
UACC-62	NFnzdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\YSGlEPTB;ND60OlU1PSEQvF2=	MlPvV2FPT0WU
MS-1	M{HsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrI[IZKSzVyPUSuOFkyOTVizszN	NXfN[2QyW0GQR1XS
RCM-1	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTRwNUK5NkDPxE1?	NG\2NmVUSU6JRWK=
IST-SL1	M{nk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL6U3BrUUN3ME20MlY2OzV7IN88US=>	MlTxV2FPT0WU
SW756	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3L1U2lEPTB;ND62PVE{PSEQvF2=	MYDTRW5ITVJ?
HCC38	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTtU3RKSzVyPUSuO\|EyQTdizszN	MoLsV2FPT0WU
YAPC	M4H2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\FPGlEPTB;ND63NVMyOyEQvF2=	NFfYOXdUSU6JRWK=
DK-MG	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHue2dKSzVyPUSuO\|gyOTJizszN	NXTZRZlUW0GQR1XS
HCC1937	M1HTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fFdGlEPTB;ND64OVEzPSEQvF2=	M{HX[HNCVkeHUh?=
OAW-28	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnDPG1LUUN3ME20MlkzPDN3IN88US=>	M{f3VHNCVkeHUh?=
MEG-01	NXfubFdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTxb2I6UUN3ME21MlA5OzJ6IN88US=>	M1vGZXNCVkeHUh?=
GI-1	NFfy[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLFTWM2OD13LkKzOFg3KM7:TR?=	M170PHNCVkeHUh?=
FADU	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;FPWlEPTB;NT6yO\|g{PyEQvF2=	NHnPbGZUSU6JRWK=
CAPAN-1	NITmOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrZTYNVUUN3ME21MlM6PDN{IN88US=>	NGHlfZRUSU6JRWK=
TGBC11TKB	NEfh[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTVwNEW3PFYh\|ryP	NX3UcYJRW0GQR1XS
DBTRG-05MG	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTPdFJPUUN3ME21MlUxPTJizszN	NWrpfYpwW0GQR1XS
ONS-76	NIizXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTVwNUW4NFEh\|ryP	NUXON3lQW0GQR1XS
Ca-Ski	NUizWoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3iTWM2OD13Lk[yOVY3KM7:TR?=	MUDTRW5ITVJ?
COLO-741	NIrGW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHnTWM2OD13LkexPVk2KM7:TR?=	NXjWeZA2W0GQR1XS
HT-29	NXfwU4lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4K2O2lEPTB;NT64NFQ4PSEQvF2=	M1jRO3NCVkeHUh?=
HCC1187	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PTPGlEPTB;NT64NVAxQCEQvF2=	M2nmdnNCVkeHUh?=
Capan-2	M4HKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTScYNKSzVyPUWuPVU6QTRizszN	M1LTdXNCVkeHUh?=
NCI-H630	MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ja[mlEPTB;Nj6xNVQ1OSEQvF2=	NFPS[lVUSU6JRWK=
COLO-678	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K2PWlEPTB;Nj6xOVA6OiEQvF2=	MoTtV2FPT0WU
D-502MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXxboFUUUN3ME22MlE4OzN4IN88US=>	MlTYV2FPT0WU
NB17	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTZwMkS5OFMh\|ryP	MWjTRW5ITVJ?
SK-MEL-24	M3jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7xTWM2OD14LkK2OFkh\|ryP	MWDTRW5ITVJ?
NCI-SNU-5	NUT6OXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NECxNnBKSzVyPU[uNlcyOThizszN	M4TZXXNCVkeHUh?=
D-392MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW3TWM2OD14LkOzN\|k6KM7:TR?=	Mm\2V2FPT0WU
A498	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHqTWM2OD14LkSwN\|AzKM7:TR?=	MoD4V2FPT0WU
OCI-AML2	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfPZWdKSzVyPU[uOFU1PDVizszN	NHHYNJFUSU6JRWK=
HCC2157	M4S4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTZwNEW2NVYh\|ryP	NUXZZZpDW0GQR1XS
C3A	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHKOG9UUUN3ME22MlUzODB2IN88US=>	NFf3dVlUSU6JRWK=
NCI-H1650	NYC0NmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr6UHdKSzVyPU[uO\|A2OjJizszN	NXTO[Ic2W0GQR1XS
DU-145	NVnXc5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TUcGlEPTB;Nj63O\|A{KM7:TR?=	NGXrOGdUSU6JRWK=
COLO-829	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjJN4VkUUN3ME22Mlc4QDd\|IN88US=>	Mn\ZV2FPT0WU
LS-1034	NFfifmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTdwMES0NVIh\|ryP	MWrTRW5ITVJ?
HCC1954	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PkSGlEPTB;Nz60PFE{PCEQvF2=	NUHqZ5kzW0GQR1XS
KURAMOCHI	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjYRolKSzVyPUeuOFg2OzNizszN	Ml3QV2FPT0WU
Mo-T	M1HlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFuxZlJKSzVyPUeuOVE1QThizszN	MVLTRW5ITVJ?
OE19	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDKNodKSzVyPUeuOlU2ODNizszN	NUPNfoo6W0GQR1XS
COR-L105	M17EcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILa[mNKSzVyPUeuO\|E1OjFizszN	MX3TRW5ITVJ?
NCI-H2342	M4LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTdwN{G1NlEh\|ryP	MWTTRW5ITVJ?
U-87-MG	M{TZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nGN2lEPTB;OD6wN\|M{PCEQvF2=	MUTTRW5ITVJ?
MKN28	NUT4OIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRThwMUG1NVUh\|ryP	Ml\sV2FPT0WU
HT-1197	NELaWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2iyT2lEPTB;OD6yOVkxPyEQvF2=	NGLNdFhUSU6JRWK=
ChaGo-K-1	NG\NSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13GOGlEPTB;OD6zOFI1PSEQvF2=	NVv1PINkW0GQR1XS
NCI-H226	NYr1NndbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nRNWlEPTB;OD60OFM{OSEQvF2=	NFXheGFUSU6JRWK=
NCI-H2029	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHNT2wxUUN3ME25MlA3PzV7IN88US=>	NVPHd3N[W0GQR1XS
TE-11	NYDX[VRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjHTWM2OD17LkS1OVg5KM7:TR?=	NFLOOGpUSU6JRWK=
ZR-75-30	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jv[WlEPTB;OT65NlY{PCEQvF2=	NIjSeJJUSU6JRWK=
SW837	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFyLkKyPVMh\|ryP	MYfTRW5ITVJ?
NCI-H1651	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFGxWFVKSzVyPUGwMlI{OjZizszN	NHPSTJNUSU6JRWK=
NCI-H727	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFyLkS0PVUh\|ryP	Mn:4V2FPT0WU
NCI-H358	M3TvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTFyLkizOlUh\|ryP	NUL6dG9[W0GQR1XS
NCI-H2087	NHmwe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkWyTWM2OD1zMT6wOFM1KM7:TR?=	M1XyW3NCVkeHUh?=
FTC-133	NWP0c4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFzLkSwOVEh\|ryP	MnHDV2FPT0WU
LAN-6	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3RTWM2OD1zMj6xNlQh\|ryP	NFLaVllUSU6JRWK=
NCI-H1838	NEfHbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHNTWM2OD1zMj61NVUyKM7:TR?=	NYT4VWc1W0GQR1XS
Calu-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzKNm5KSzVyPUG0MlExOjFizszN	M3G4SXNCVkeHUh?=
HCC70	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTF2LkS1NUDPxE1?	M3vWZXNCVkeHUh?=
KARPAS-299	MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF3LkKxOVkh\|ryP	NXzFVnQ4W0GQR1XS
CAL-27	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF3LkO4OFMh\|ryP	MX;TRW5ITVJ?
NCI-H82	NGHUNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13mWWlEPTB;MUWuOVMzKM7:TR?=	NVnmTWllW0GQR1XS
no-10	M37sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;0TWM2OD1zNT65N\|gh\|ryP	NEHKcYZUSU6JRWK=
U251	NUnWS\|ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfYVWFKSzVyPUG2MlM3PzVizszN	NXPEe3F[W0GQR1XS
TE-9	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HDfGlEPTB;MUeuOVE3PiEQvF2=	NYrFfpN1W0GQR1XS
TE-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF7LkC2NFch\|ryP	M334TnNCVkeHUh?=
COLO-824	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPsTWM2OD1{MD65Nlc3KM7:TR?=	NIjZW3lUSU6JRWK=
HuP-T3	M2H3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJzLkC3OFgh\|ryP	M3r0O3NCVkeHUh?=
KALS-1	NEnhT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPWSFdKSzVyPUKxMlE4PSEQvF2=	NGLXZ2lUSU6JRWK=
L-428	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv0TWM2OD1{MT60NFE3KM7:TR?=	MW\TRW5ITVJ?
JAR	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJzLkWwNkDPxE1?	MoTRV2FPT0WU
DoTc2-4510	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfaT3ZIUUN3ME2yN{45PDd3IN88US=>	M4rR[3NCVkeHUh?=
ABC-1	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJ4Lke5OVch\|ryP	NFy5TGVUSU6JRWK=
MHH-NB-11	NYi5R\|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTN\|LkO0OlQh\|ryP	M4TodXNCVkeHUh?=
SW1463	NYq5boZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHmTWM2OD1\|Mz65PFMh\|ryP	NH3WVVRUSU6JRWK=
SW1417	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfGTWM2OD1\|Nz6wPVUzKM7:TR?=	NYfYUG55W0GQR1XS
NB12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTN7LkS2OVUh\|ryP	MYfTRW5ITVJ?
NY	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTRzLkOyNFEh\|ryP	M1TKT3NCVkeHUh?=
H1048	NWntc2FbSXCxcITvd4l{KEG\|c3H5	MnzvOVAxKG6P	MXK3NkBp		NEPKW2NvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MWOyOVc{PzV2Mh?=
H86	NH;pbodCeG:ydH;zbZMhSXO\|YYm=	NXfEWnF[PTByIH7N	NXvBbFBlPzJiaB?=		M3m0To5p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	M{HOWFI2PzN5NUSy
H196	M3TqOWFxd3C2b4Ppd{BCe3OjeR?=	MUG1NFAhdk1?	MUK3NkBp		NIDsPYNvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	NYD0PJRuOjV5M{e1OFI>
H446	MVHBdI9xfG:\|aYOgRZN{[Xl?	NGXrNWs2ODBibl2=	NVvDTFVLPzJiaB?=		MX3ubIFv[2W\|IFHCWE0zPjQkgKPpcoR2[2WmIHHwc5B1d3Orcx?=	NWTOOYFYOjV5M{e1OFI>
TFK-1	NXf5bGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmC3O\|IhcA>?	MVPEUXNQ	Mli2TWM2OD12NzDuUS=>	NELxV5AzPTF3MkK0OC=>
EGI-1	M1PZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVHl[I1xPzJiaB?=	NYTJVm1HTE2VTx?=	NUXsXZpDUUN3ME21N{BvVQ>?	Moq3NlUyPTJ{NES=
OCI/AML3	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnW[lgxNjJizszN	MlzZOFghcA>?		MYPlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	NUHZfGtSOjR5M{mzPVM>
U937	M2Lsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3P6U\|AvOiEQvF2=	M3TPT\|Q5KGh?		MmXt[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	MVSyOFc{QTN7Mx?=
MOLM13	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSwNE4zKM7:TR?=	M1\pWVQ5KGh?		MlHJ[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	NYXiXGlzOjR5M{mzPVM>
MCF7	M17DWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDkNI0zOCCwTR?=	M33rWlczKGh?	NXTKdo9JTkKV	MYDy[YR2[2W\|IITo[UBRTUySMT3t[YRq[XSnZDDpcoNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eR?=	NYXjU2NCOjR4OEiwOFY>
TamR	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLXOlFzUUN3ME2xPQKBkW6P	NXy5TFl6OjR2NUewOlk>
MCF7-X	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHOTWM2OD1{NDDuUS=>	NVjPdWxKOjR2NUewOlk>
T47D-tamR	M33lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF7IH7N	NXi0XmJ5OjR2NUewOlk>
293T	MmDOSpVv[3Srb36gRZN{[Xl?	MWOyNEBvVQ>?	NWm4dmV7OyCq		MXjkbZNzfXC2czDBb5QudWWmaXH0[YQhXEmILVnBJJN1[WKrbHn0fUwhfHKjboPsc4NifGmxbjygZY5lKGGldHn2bZR6	NFXo[IYzPDN4M{S0PS=>
SW620	NYOyfpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjmZ2NqOC5yMEGtNVDPxE1?	M1PBU\|I1KGh?		MV3pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG\|IITo[UBkd26lZX70doF1cW:wIILpd4V{	MXSyOFM3OzR2OR?=
Huh7	M4nOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXS1MVExOCCwTR?=	NWe5U4VKOC1{NDDo	MUXEUXNQ	M{nUU4lv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MnWwNlQzQTd\|MEC=
Hep3B	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHkcIg2NTFyMDDuUS=>	NHf6S5gxNTJ2IHi=	MU\EUXNQ	MXPpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MmLUNlQzQTd\|MEC=
Huh7	NVjaN3N5TnWwY4Tpc44hSXO\|YYm=	Mn:3NVAxKG6P	MX[xNkBp	NH[zfFdFVVOR	MVzpcoR2[2W\|IHH1eI9xcGGpedMg	M2HLRVI1Ojl5M{Cw
U87-MG	M2\Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXq3NkBp		NGC4NoFIUTVy4pEJQgKBkTd7IH7NxsA>	MoexNlQzPDl4NEC=
L3.6pl	M4nLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPDdoNDOSEQvF2=	MmTlO\|IhcA>?		MWHpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBDVVNvN{e3OlA4	MUmyOFI{OzN7OR?=
TE671	MnHDRZBweHSxc3nzJGF{e2G7	M3P0RlEh\|ryP	M2rhdlQ5KGh?		NUDHTnc4cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	NVHNb3hpOjRzM{OyNVg>
RD	NIHnc25CeG:ydH;zbZMhSXO\|YYm=	NIjuVXcyKM7:TR?=	NFPnboE1QCCq		Mn\QbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	NYnlOIVXOjRzM{OyNVg>
RMS13	MoD1RZBweHSxc3nzJGF{e2G7	MY[xJO69VQ>?	MVe0PEBp		M33uNolv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	NUfndIJ2OjRzM{OyNVg>
RH30	NEC5UmpCeG:ydH;zbZMhSXO\|YYm=	NXLRV4E3OSEQvF2=	NUXvb3NSPDhiaB?=		MnjIbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	M2PDO\|I1OTN\|MkG4
Hep-2	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzVNE4xOS1zIN88US=>	Mm\FNVIuQTZiaB?=		MmLlbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NWT4XmxvOjRzMEO3OFk>
SCC-9	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrjUYsxNjBzLUGg{txO	NIPib3AyOi17NjDo		NUTkepoxcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NUP3dnhLOjRzMEO3OFk>
Hep-2	M3rJNWZ2dmO2aX;uJGF{e2G7	NETDRm4xNjFxMD61JO69VQ>?	M32zc\|I1KGh?		MoixZoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	MnzPNlQyODN5NEm=
SCC-9	NVi4UHRpTnWwY4Tpc44hSXO\|YYm=	NWDUbnpJOC5zL{CuOUDPxE1?	NEf5PWgzPCCq		MWficI9kc3NibWTPVmMyKGGwZDDtWG9TSzJiYXP0bZZifGmxbh?=	MkPLNlQyODN5NEm=
PANC-1	NFyyO4VCeG:ydH;zbZMhSXO\|YYm=	NUnYcYh3PTByIH7N	NF35bnY1QCCq		Mn;md4Vve2m2aYrld{Bx[W6lcnXheIlkKGOjbnPldkBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	M3j5TVI{QDh4Mkm0
RMG2	NH;tfFVCeG:ydH;zbZMhSXO\|YYm=	M2fYUVEuOTByMDDuUS=>	MY[3NkBp	NVnlWmkzTkKV	NWD5VGVvcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	MYmyN\|YyPTZ\|MR?=
HAC2	MYjBdI9xfG:\|aYOgRZN{[Xl?	MkjCNU0yODByIH7N	MVm3NkBp	M3[zSmZDWw>?	MWXpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	NX;hO3BsOjN4MUW2N\|E>
HT-29	MVfBdI9xfG:\|aYOgRZN{[Xl?	NVToc\|dxOSEQvF2=	NIfI[2I4OiCq		NGPrT2xifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	MXSyNVk1QTF{MR?=
DLD1	NI\aVGJCeG:ydH;zbZMhSXO\|YYm=	MXSxJO69VQ>?	Moi4O\|IhcA>?		Mke5ZZR1\W63YYTld{A2NU[XLXnu[JVk\WRiY3XscEBl\WG2aB?=	M130W\|IyQTR7MUKx
HT-29	NYPwUGlETnWwY4Tpc44hSXO\|YYm=	NIfvflYyKM7:TR?=	Mm\hO\|IhcA>?		M4PWR4lv\HWlZYOgZZV1d3CqYXf5JJRwKGOxbn\ldkBkgXSxcILveIVkfGmxbh?=	NFLGTJQzOTl2OUGyNS=>
DLD1	NGfuR2dHfW6ldHnvckBCe3OjeR?=	MUOxJO69VQ>?	NEnBVJM4OiCq		M17mdolv\HWlZYOgZZV1d3CqYXf5JJRwKGOxbn\ldkBkgXSxcILveIVkfGmxbh?=	M{DZblIyQTR7MUKx
Rh41	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rmSGlEPTB;M{CuO{BvVQ>?	NVrQd3VjOjF\|M{e2O\|k>
Rh18	M1T1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTRzLkSgcm0>	M1jEd\|IyOzN5Nke5
Rh30	NELF[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\HV5JKSzVyPUG0JI5O	NXfiend5OjF\|M{e2O\|k>
BT-12	NEnITFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXztRlhXUUN3ME2yOE44KG6P	MV2yNVM{PzZ5OR?=
CHLA-266	M1P6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPmeIZKSzVyPUGuNUBvVQ>?	NUf1XmJJOjF\|M{e2O\|k>
TC-71	NVX3d29vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nRTmlEPTB;NE[uOUBvVQ>?	MknONlE{Ozd4N{m=
CHLA-9	NVX1SGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHWTWM2OD1zNT6zJI5O	NW\LN2s{OjF\|M{e2O\|k>
CHLA-10	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTNwOTDuUS=>	NV\xdmdCOjF\|M{e2O\|k>
CHLA-258	NWPy[ZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HUVWlEPTB;MUCuOEBvVQ>?	NX7KRWQ6OjF\|M{e2O\|k>
GBM2	NFyxN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTWbpQ4UUN3ME20NE44KG6P	NIX3TpczOTN\|N{[3PS=>
NB-1643	M{WzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3aVFBKSzVyPUOzMlghdk1?	MmSzNlE{Ozd4N{m=
NB-EBc1	M{TmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13UOGlEPTB;MkeuNUBvVQ>?	M{TPOVIyOzN5Nke5
CHLA-90	NELsbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTN2LkWgcm0>	M1;G[\|IyOzN5Nke5
CHLA-136	NFK4cVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPielduUUN3ME2xOlIvPiCwTR?=	MoW5NlE{Ozd4N{m=
NALM-6	NILUXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Lld2lEPTB;M{KuPUBvVQ>?	MnXQNlE{Ozd4N{m=
COG-LL-317	M4ruSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPEUmpOUUN3ME2xMlMhdk1?	MkTMNlE{Ozd4N{m=
RS4;11	M3HkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkGyTWM2OD1\|NTDuUS=>	Mmf6NlE{Ozd4N{m=
MOLT-4	NUXscVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRThwNjDuUS=>	M4fMflIyOzN5Nke5
CCRF-CEM	MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTRwMTDuUS=>	NV;mOFIxOjF\|M{e2O\|k>
Kasumi-1	M1[1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTFwNDDuUS=>	MX:yNVM{PzZ5OR?=
Karpas-299	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTDTWM2OD1{MT63JI5O	MlTSNlE{Ozd4N{m=
Ramos-RA1	NHPzZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P4SmlEPTB;OD6yJI5O	NW\MdppnOjF\|M{e2O\|k>
H838	NF7OTmZHfW6ldHnvckBCe3OjeR?=	MWmxJO69VQ>?	NFT1WlQ1QCCq		NGDCZ21qdmS3Y3XzJINmdGxiYYX0c5Bp[We7	MUWyNFM3PDFzMx?=
H838	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;3NE0{KM7:TR?=	NHiwSnA4OiCq		NY\DdI5KcW6mdXPld{Boem:5dHigbY5pcWKrdHnvckBidmRiYYX0c5Bp[We7	NXTD[mVWOjByMki4OVQ>
A549	NGDCSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vBSVAuOyEQvF2=	Ml\LO\|IhcA>?		M{LKT4lv\HWlZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKGG3dH;wbIFogQ>?	NUXEbVc1OjByMki4OVQ>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Water	Insoluble
	Ethanol	'3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(CO)C=C(C=C1)C2=NC3=C(C=C2)C(=NC(=N3)N4CCOCC4C)N5CCOCC5C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055